Molecular Classification
G protein-coupled receptor, Receptor, Adrenergic receptor
Other Names
Alpha-2 adrenergic receptor, α2-adrenergic receptor, Adrenoceptor alpha 2A/B/C, ADRA2A, ADRA2B, ADRA2C
Disease Roles
Cardiovascular disease (e.g., hypertension)Neuropsychiatric disorders (e.g., ADHD, anxiety, depression, withdrawal syndromes)Pain and anesthesia/sedation

Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptor Overview

The Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptors are closely related subtypes of G protein-coupled receptors that bind the endogenous catecholamines norepinephrine and epinephrine and regulate the sympathetic nervous system both centrally and peripherally[5][1][9][4]. The subtypes differ in tissue distribution and physiological roles: - Alpha-2A regulates neurotransmitter release at high-frequency stimulation, is predominant in CNS inhibition of norepinephrine release, and is a key target for antihypertensives and sedatives[5][1][3]. - Alpha-2B is expressed mainly in peripheral vasculature and mediates vasoconstrictive responses. - Alpha-2C modulates neurotransmitter release during lower levels of stimulation and plays roles in stress response and cognitive function[5]. Many drugs act as agonists or antagonists at these sites for indications such as hypertension, attention-deficit hyperactivity disorder, anesthetic adjunct (sedation/analgesia), withdrawal syndromes, and some eye diseases[2][8][4]. Adverse effects result mainly from excessive reduction in sympathetic tone. These receptors are well-validated molecular targets but should ideally be treated individually in structured data systems rather than as a combined group.

Mechanism of Action

Agonists stimulate presynaptic α2-adrenergic receptors, inhibiting norepinephrine release in the CNS, resulting in decreased sympathetic outflow, vasodilation, reduced peripheral resistance, and lowered blood pressure - Antagonists inhibit these receptors, promoting neurotransmitter release and increased sympathetic activity

Biological Functions

Signal transduction
Regulation of neurotransmitter release
Modulation of sympathetic nervous system activity
Inhibition of norepinephrine/epinephrine release
Regulation of vascular tone and smooth muscle contraction

Disease Associations

Cardiovascular disease (e.g., hypertension)
Neuropsychiatric disorders (e.g., ADHD, anxiety, depression, withdrawal syndromes)
Pain and anesthesia/sedation
Addiction/withdrawal

Safety Considerations

  • Hypotension
  • Bradycardia
  • Sedation
  • Dry mouth
  • Withdrawal syndromes (rebound hypertension on abrupt discontinuation)
  • CNS depression
  • Risk of misuse (in the case of drugs like xylazine adulteration)

Interacting Drugs

Clonidine
Guanfacine
Methyldopa
Brimonidine
Dexmedetomidine
Tizanidine
Xylazine
Lofexidine
Detomidine
Medetomidine
Apraclonidine
GuanaBenz
Atipamezole (antagonist)
Yohimbine (antagonist)
Mirtazapine (antagonist)

Associated Biomarkers

Biomarker
No well-established clinical biomarkers specific for α2A/2B/2C adrenergic receptor pharmacodynamics; genetic variants in ADRA2A may be under investigation in pharmacogenetics research